Optimer names Pedro Lichtinger president, CEO

Pedro Lichtinger is set to become Optimer Pharmaceuticals' president and CEO. He also will join the company's board of directors. Release

Julian Chick has resigned from the board of Avexa and will leave his position as the CEO at the end of the month. Release

Strides Arcolab has tapped Manish Gupta as CEO of its pharma business. Release

InteKrin Therapeutics has named Linda Slanec Higgins as its president and CEO. Release

The board of BioPhausia has appointed Maris Hartmanis as the company's new CEO. Release

Coronado Biosciences has named Gary Gemignani as COO and CFO.  Release

Ampio Pharmaceuticals has tapped Bruce Miller to become its new CFO. In addition, Michael Macaluso will become chairman of the board of directors, replacing David Bar-Or, who remains the chief scientific officer and a member of the board. Release

Radient Pharmaceuticals has announced the appointment of  Afsaneh Motamed-Khorasani as director of oncology. Release

Officials of Kylin Therapeutics report that Henry Li will serve in the newly created position as director for the company's R&D team. Release

Fate Therapeutics has named Tom Novak as VP of research and drug discovery. Release

N30 Pharma has expanded its board of directors, adding Howard Furst of Deerfield Management. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.